Proficio Capital Partners LLC Purchases New Position in Thermo Fisher Scientific Inc. $TMO

Proficio Capital Partners LLC acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the 2nd quarter, Holdings Channel.com reports. The firm acquired 1,412 shares of the medical research company’s stock, valued at approximately $708,000.

Several other hedge funds have also made changes to their positions in the company. J. Stern & Co. LLP increased its stake in shares of Thermo Fisher Scientific by 58,006.4% during the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock valued at $18,258,082,000 after buying an additional 31,455,105 shares during the period. BlackRock Inc. purchased a new stake in Thermo Fisher Scientific in the second quarter worth about $15,501,867,000. State Street Corp increased its position in Thermo Fisher Scientific by 1.4% during the 4th quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock valued at $9,633,991,000 after purchasing an additional 229,630 shares during the period. Corient Private Wealth LP bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $382,547,000. Finally, Capital World Investors lifted its position in shares of Thermo Fisher Scientific by 7.0% in the 4th quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock worth $6,376,229,000 after purchasing an additional 718,669 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Michael D. Shafer sold 25,500 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the transaction, the executive vice president directly owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. This trade represents a 54.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer owned 2,966 shares in the company, valued at approximately $1,734,546.46. The trade was a 12.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 73,768 shares of company stock valued at $44,122,820 over the last ninety days. 0.33% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on TMO shares. Wells Fargo & Company cut their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. HSBC cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating and dropped their target price for the company from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Jefferies Financial Group reissued a “buy” rating and issued a $630.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Weiss Ratings raised Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday. Finally, Morgan Stanley lifted their target price on Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus price target of $619.41.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $600.32 on Wednesday. The firm’s fifty day simple moving average is $564.35 and its two-hundred day simple moving average is $512.92. The firm has a market capitalization of $221.97 billion, a P/E ratio of 32.29, a P/E/G ratio of 2.58 and a beta of 0.85. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $647.00.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.11%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.